• 1
    Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancers. Science 1991; 253: 4953.
  • 2
    Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1991; 252: 170811.
  • 3
    Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985; 45: 143743.
  • 4
    Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299303.
  • 5
    Tokino T, Thiagalingam S, El-Deiry WS, Waldman T, Kinzler KW, Vogelstein B. p53 tagged sites from human genomic DNA. Hum Mol Genet 1994; 3: 153742.
  • 6
    Furuhata T, Urano T, Tokino T, Nakamura Y. Isolation of a novel GPI-anchored gene specifically regulated by p53, and correlation between its expression and anti-cancer drug sensitivity. Oncogene 1996; 13: 196570.
  • 7
    Nishimori H, Shiratsuchi T, Urano T, Kimura Y, Kiyono K, Tatsumi K, Yoshida S, Ono M, Kuwano M, Nakamura Y, Tokino T. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type1 repeats inhibits experimental angiogenesis. Oncogene 1997; 15: 214550.
  • 8
    Takei Y, Ishikawa S, Tokino T, Muto T, Nakamura Y. Isolation of a novel p53-target gene from a colon-cancer cell line carrying a highly-regulated wild-type p53 expression system. Genes Chromosom Cancer 1998; 23: 19.
  • 9
    Okamura S, Ng CC, Koyama K, Takei Y, Monden M, Nakamura Y. Identification of seven genes regulated by wild-type p53 in a colon-cancer cell line carrying a well-controlled wild-type p53 expression system. Oncol Res 1999; 11: 2815.
  • 10
    Tanaka H, Arakawa H, Shiraishi K, Yamaguchi T, Takei Y, Nakamura Y. A ribonucleotide reductase gene involved in a p53 dependent DNA damage checkpoint. Nature 2000; 404: 429.
  • 11
    Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y, Arakawa H. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell-cycle checkpoint. Cancer Res 2001; 61: 825662.
  • 12
    Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 2003; 34: 4405.
  • 13
    Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. Isolation of a novel gene encoding a mitochondrial protein, p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser46-phosphorylated p53. Cell 2000; 102: 84962.
  • 14
    Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, Arakawa H. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 2002; 62: 28839.
  • 15
    Kimura Y, Furuhata T, Urano T, Hirata K, Nakamura Y, Tokino T. Genomic structure and chromosomal localization of GML (GPI-anchored molecule-like protein), a gene induced by p53. Genomics 1997; 41: 47780.
  • 16
    Ueda K, Miyoshi Y, Tokino T, Watatani M, Nakamura Y. Induction of apoptosis in T98G glioblastoma cells by transfection of GML, a p53-target gene. Oncol Res 1999; 11: 12532.
  • 17
    Iiizumi M, Arakawa H, Mori T, Ando A, Nakamura Y. Isolation of a novel human p53-target gene encoding a mitochondrial protein, p53ABC1L, that is highly homologous to yeast activity of bc1 complex. Cancer Res 2002; 62: 124650.
  • 18
    Anazawa Y, Arakawa H, Nakagawa H, Nakamura Y. Identification of STAG1 as a key mediator of a p53-dependent apoptotic pathway. Oncogene in press.
  • 19
    Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 15824.
  • 20
    Oda K, Shiratsuchi T, Nishimori H, Inazawa J, Yoshikawa H, Taketani Y, Nakamura Y, Tokino T. Identification of BAIAP2 (BAI-associated protein 2), a novel human homologue of hamster IRSp53, whose SH3 domain interacts with the cytoplasmic domain of BAI1. Cytogenet Cell Genet 1999; 84: 7582.
  • 21
    Han HJ, Tokino T, Nakamura Y. CSR, a scavenger receptor-like gene with a protective role from cell death caused by UV irradiation and oxidative stress. Hum Mol Genet 1998; 7: 103946.
  • 22
    Shiraishi K, Fukuda S, Mori T, Matsuda K, Yamaguchi T, Tanikawa C, Ogawa M, Nakamura Y, Arakawa H. Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53. Cancer Res 2000; 60: 37226.
  • 23
    Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 2002; 21: 29148.
  • 24
    Mori T, Anazawa Y, Matsui K, Fukuda S, Nakamura Y, Arakawa H. Cyclin K as a direct transcriptional target of the p53 tumor suppressor. Neoplasia 2002; 4: 26874.
  • 25
    Kimura T, Gotoh M, Nakamura Y, Arakawa H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Science 2003; 94: 4316.
  • 26
    Ng CC, Arakawa H, Fukuda S, Kondoh H, Nakamura Y. p53RFP, a p53-inducible RING-finger protein, regulates the stability of p21WAF1. Oncogene 2003; 22: 444958.
  • 27
    Tanikawa C, Matsuda K, Fukuda S, Nakamura Y, Arakawa H. p53RDL1UNC5B as a positive and negative regulator of p53-dependent apoptosis. Nature Cell Biol 2003; 5: 21623.
  • 28
    Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y, Monden M, Nakamura Y. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 2001; 8: 8594.